@article{eeaa28b4f7e64db5ba8eb61a2ebc54d1,
title = "Extracorporeal carbon dioxide removal for lowering the risk of mechanical ventilation: research questions and clinical potential for the future",
abstract = "As a result of technical improvements, extracorporeal carbon dioxide removal (ECCO2R) now has the potential to play an important role in the management of adults with acute respiratory failure. There is growing interest in the use of ECCO2R for the management of both hypoxaemic and hypercapnic respiratory failure. However, evidence to support its use is scarce and several questions remain about the best way to implement this therapy, which can be associated with serious side-effects. This Review reflects the consensus opinion of an international group of clinician scientists with expertise in managing acute respiratory failure and in using ECCO2R therapies in this setting. We concisely review clinically relevant aspects of ECCO2R, and provide a series of recommendations for clinical practice and future research, covering topics that include the practicalities of ECCO2R delivery, indications for use, and service delivery.",
author = "{International ECMO Network (ECMONet)} and Boyle, {Andrew J.} and Sklar, {Michael C.} and McNamee, {James J.} and Daniel Brodie and Slutsky, {Arthur S.} and Laurent Brochard and McAuley, {Daniel F.} and D. Abrams and A. Combes and E. Fan and J. Fraser and C. Hodgson and N. Patroniti and A. Pesenti and {Mac Sweeney}, R. and J. Manacebo and T. Mueller and T. Pham and M. Ranieri and M. Schmidt and K. Shekar",
note = "Funding Information: AJB, JJMcN, and DFMcA report grants from Northern Ireland Health and Social Care Research and Development Agency and NIHR HTA, with in-kind support from ALung Technologies, Inc, for a clinical trial of ECCO 2 R. ALung Technologies, Inc, have no role in the study design or conduct. MCS has nothing to disclose. DB is currently the co-chair of the Trial Steering Committee for the VENT-AVOID trial sponsored by ALung Technologies, and was previously on the medical advisory board of ALung Technologies and Kadence. All compensation for these activities is paid to Columbia University. He is also currently consulting for Baxter. ASS reports personal fees from Baxter, Maquet Critical Care, Novalung/Xenios, during the writing of the Review and from Bayer, Faron, and Ferring, outside of the submitted work. LB reports grants from Medtronic Covidien, non-financial support from General Electric, Philips, and Air Liquide, and grants and non-financial support from Fisher Paykel, outside of the submitted work. Outside of the submitted work, DFMcA reports personal fees from consultancy for Peptinnovate, Bayer, GlaxoSmithKline, Boehringer Ingelheim; he has also received grants from NIHR and other funders as an investigator for clinical trials in ARDS; his institution has received funding from GlaxoSmithKline for undertaking bronchoscopy as part of a clinical trial. In addition, DFMcA has a patent US8962032 for a novel treatment for ARDS issued to his institution. Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",
year = "2018",
month = nov,
doi = "10.1016/S2213-2600(18)30326-6",
language = "English (US)",
volume = "6",
pages = "874--884",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Ltd",
number = "11",
}